Circulating human papillomavirus DNA as a marker for disease extent and recurrence among patients with oropharyngeal cancer

Cancer

Volumn 121, Issue 19, 2015, Pages 3455-3464

  Dahlstrom, Kristina R ^a   Li, Guojun ^a   Hussey, Caroline S ^a   Vo, Jenny T ^a   Wei, Qingyi ^a,b   Zhao, Chong ^a   Sturgis, Erich M ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

head and neck neoplasms; human papillomavirus (HPV); oropharyngeal cancer; serum HPV DNA; survival

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DETERMINATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OROPHARYNX CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; BLOOD; CASE CONTROL STUDY; COHORT ANALYSIS; GENETICS; HUMAN PAPILLOMAVIRUS TYPE 16; MORTALITY; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; PROGNOSIS; PROSPECTIVE STUDY; TUMOR RECURRENCE; VIROLOGY;

CASE-CONTROL STUDIES; COHORT STUDIES; DNA, VIRAL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84941936269     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29538     Document Type: Article

References (36)

1. D'Souza G, Kreimer AR, Viscidi R, et al., Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007; 356: 1944-1956.
2. Nasman A, Attner P, Hammarstedt L, et al., Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer. 2009; 125: 362-366.
3. Attner P, Du J, Nasman A, et al., The role of human papillomavirus in the increased incidence of base of tongue cancer. Int J Cancer. 2010; 126: 2879-2884.
4. Chaturvedi AK,. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health. 2010; 46 (suppl 4): S20-S26.
5. Chaturvedi AK, Engels EA, Pfeiffer RM, et al., Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011; 29: 4294-4301.
6. Fakhry C, Westra WH, Li S, et al., Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008; 100: 261-269.
7. Ang KK, Harris J, Wheeler R, et al., Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010; 363: 24-35.
8. Posner MR, Lorch JH, Goloubeva O, et al., Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol. 2011; 22: 1071-1077.
9. Schwarzenbach H, Hoon DS, Pantel K,. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011; 11: 426-437.
10. Lo YM, Chan LY, Lo KW, et al., Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 1999; 59: 1188-1191.
11. Leung SF, Zee B, Ma BB, et al., Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol. 2006; 24: 5414-5418.
12. Lo YM, Leung SF, Chan LY, et al., Plasma cell-free Epstein-Barr virus DNA quantitation in patients with nasopharyngeal carcinoma. Correlation with clinical staging. Ann N Y Acad Sci. 2000; 906: 99-101.
13. Ferrari D, Codeca C, Bertuzzi C, et al., Role of plasma EBV DNA levels in predicting recurrence of nasopharyngeal carcinoma in a Western population. BMC Cancer. 2012; 12: 208.
14. Chai SJ, Pua KC, Saleh A, et al,; Malaysian NPC Study Group, Teo SH, Khoo AS, Yap LF,. Clinical significance of plasma Epstein-Barr virus DNA loads in a large cohort of Malaysian patients with nasopharyngeal carcinoma. J Clin Virol. 2012; 55: 34-39.
15. Hsu CL, Chan SC, Chang KP, et al., Clinical scenario of EBV DNA follow-up in patients of treated localized nasopharyngeal carcinoma. Oral Oncol. 2013; 49: 620-625.
16. Wang WY, Twu CW, Chen HH, et al., Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels. Cancer. 2013; 119: 963-970.
17. Capone RB, Pai SI, Koch WM, et al., Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma. Clin Cancer Res. 2000; 6: 4171-4175.
18. Cao H, Banh A, Kwok S, et al., Quantitation of human papillomavirus DNA in plasma of oropharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys. 2012; 82: e351-e358.
19. Ahn SM, Chan JY, Zhang Z, et al., Saliva and plasma quantitative polymerase chain reaction-based detection and surveillance of human papillomavirus-related head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2014; 140: 846-854.
20. Sathish N, Abraham P, Peedicayil A, et al., HPV DNA in plasma of patients with cervical carcinoma. J Clin Virol. 2004; 31: 204-209.
21. Kay P, Allan B, Denny L, Hoffman M, Williamson AL,. Detection of HPV 16 and HPV 18 DNA in the blood of patients with cervical cancer. J Med Virol. 2005; 75: 435-439.
22. Pornthanakasem W, Shotelersuk K, Termrungruanglert W, Voravud N, Niruthisard S, Mutirangura A,. Human papillomavirus DNA in plasma of patients with cervical cancer. BMC Cancer. 2001; 1: 2.
23. Widschwendter A, Blassnig A, Wiedemair A, Muller-Holzner E, Muller HM, Marth C,. Human papillomavirus DNA in sera of cervical cancer patients as tumor marker. Cancer Lett. 2003; 202: 231-239.
24. Dong SM, Pai SI, Rha SH, et al., Detection and quantitation of human papillomavirus DNA in the plasma of patients with cervical carcinoma. Cancer Epidemiol Biomarkers Prev. 2002; 11: 3-6.
25. Lin JC, Wang WY, Chen KY, et al., Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004; 350: 2461-2470.
26. Shao JY, Li YH, Gao HY, et al., Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Cancer. 2004; 100: 1162-1170.
27. Twu CW, Wang WY, Liang WM, et al., Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2007; 67: 130-137.
28. Lo YM, Chan LY, Chan AT, et al., Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res. 1999; 59: 5452-5455.
29. Stanley MA, Pett MR, Coleman N,. HPV: from infection to cancer. Biochem Soc Trans. 2007; 35 (pt 6): 1456-1460.
30. Sathish N, Abraham P, Peedicayil A, Sridharan G, John S, Chandy G,. Human papillomavirus 16 E6/E7 transcript and E2 gene status in patients with cervical neoplasia. Mol Diagn. 2004; 8: 57-64.
31. Mutirangura A,. Serum/plasma viral DNA: mechanisms and diagnostic applications to nasopharyngeal and cervical carcinoma. Ann N Y Acad Sci. 2001; 945: 59-67.
32. Liang C, Marsit CJ, McClean MD, et al., Biomarkers of HPV in head and neck squamous cell carcinoma. Cancer Res. 2012; 72: 5004-5013.
33. Snow AN, Laudadio J,. Human papillomavirus detection in head and neck squamous cell carcinomas. Adv Anat Pathol. 2010; 17: 394-403.
34. Jordan RC, Lingen MW, Perez-Ordonez B, et al., Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials. Am J Surg Pathol. 2012; 36: 945-954.
35. Smeets SJ, Hesselink AT, Speel EM, et al., A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer. 2007; 121: 2465-2472.
36. Singhi AD, Westra WH,. Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer. 2010; 116: 2166-2173.